• ABOUT US
    ▼
    • Our Vision
    • Leadership Team
  • OUR RESEARCH
    ▼
    • Our Approach
    • Publications
    • Conferences
  • PROGRAMS
    ▼
    • Pipeline
    • VIS649 Sibeprenlimab
    • VIS171
    • VIS513
  • FOR PATIENTS
    ▼
    • Clinical Trials
    • IgA Nephropathy
  • CAREERS
    ▼
    • Open Positions & Benefits
    • Our Culture
    • Co-op program
  • Contact

Visterra

We Bring Better Biologics to Life

  • ABOUT US
    • Our Vision
    • Leadership Team
  • OUR RESEARCH
    • Our Approach
    • Publications
    • Conferences
  • PROGRAMS
    • Pipeline
    • VIS649 Sibeprenlimab
    • VIS171
    • VIS513
  • FOR PATIENTS
    • Clinical Trials
    • IgA Nephropathy
  • CAREERS
    • Open Positions & Benefits
    • Our Culture
    • Co-op program
  • Contact

Recognition of heparan sulfate by clinical strains of dengue virus serotype 1 using recombinant subviral particles.

May 22, 2013 | Virus Research
Charlermchai Artpradit et al.

Recognition of heparan sulfate by clinical strains of dengue virus serotype 1 using recombinant subviral particles.

Charlermchai Artpradit, Luke N Robinson, Boris K Gavrilov, Troy T Rurak, Mathuros Ruchirawat, Ram Sasisekharan

>READ

© 2023 Visterra, Inc. Terms of usePrivacy PolicySite Design: Fassino/Design